Pacific Biosciences Of California (PACB) Return on Capital Employed Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1,962.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 214.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 31.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 355.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -846.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,318.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -247.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 362.00 |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | 193.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.00 |
| Dec 31, 2025 | -5,676.00 |
| Sep 30, 2025 | -7,250.00 |
| Jun 30, 2025 | -7,460.00 |
| Mar 31, 2025 | -7,151.00 |
| Jun 30, 2024 | -1,835.00 |
| Mar 31, 2024 | -667.00 |
| Dec 31, 2023 | 1,339.00 |
| Sep 30, 2023 | 5,782.00 |
| Jun 30, 2023 | 8,918.00 |
| Mar 31, 2023 | 15,311.00 |
| Dec 31, 2022 | 8,263.00 |
| Sep 30, 2022 | 8,907.00 |
| Jun 30, 2022 | 7,177.00 |
| Mar 31, 2022 | 6,951.00 |
| Jun 30, 2021 | 6,046.00 |
| Mar 31, 2021 | 5,884.00 |
| Dec 31, 2020 | 4,062.00 |
| Sep 30, 2020 | -1,428.00 |
| Jun 30, 2020 | -4,155.00 |
| Mar 31, 2020 | -9,857.00 |
| Dec 31, 2019 | -3,822.00 |
| Sep 30, 2019 | -6,127.00 |
| Jun 30, 2019 | -5,537.00 |
| Mar 31, 2019 | -5,331.00 |
| Dec 31, 2018 | -2,975.00 |
| Sep 30, 2018 | 1,152.00 |
| Jun 30, 2018 | 2,069.00 |
| Mar 31, 2018 | 1,102.00 |
| Dec 31, 2017 | -470.00 |
| Sep 30, 2017 | 136.00 |
| Jun 30, 2017 | 88.00 |
| Mar 31, 2017 | -1,028.00 |
| Dec 31, 2016 | -89.00 |
| Sep 30, 2016 | 2,399.00 |
| Mar 31, 2015 | -2,826.00 |
| Dec 31, 2014 | -1,610.00 |
| Sep 30, 2014 | -1,055.00 |